Intellia Therapeutics (NTLA) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45826J1051
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading genome editing company that specializes in developing cutting-edge curative therapeutics. The company boasts a robust pipeline of in vivo programs such as NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema. Additional product candidates include NTLA-2003 for alpha-1 antitrypsin deficiency liver disease, NTLA-3001 for alpha-1 antitrypsin deficiency lung disease, and NTLA-6001 for CD30+ lymphomas.
Intellia's focus extends to programs targeting hemophilia A and hemophilia B, as well as an ex vivo pipeline featuring NTLA-5001 for acute myeloid leukemia. The company also pioneers engineered cell therapies for the treatment of cancers and autoimmune diseases.
Moreover, Intellia offers innovative tools like the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Through strategic collaborations, Intellia partners with industry leaders such as Regeneron Pharmaceuticals, Inc., AvenCell Therapeutics, Inc., and SparingVision SAS to co-develop groundbreaking therapies for various medical conditions.
Established in 2014 and headquartered in Cambridge, Massachusetts, Intellia Therapeutics, Inc. continues to make significant strides in the field of genome editing. To learn more about their groundbreaking work, visit their website at https://www.intelliatx.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
NTLA Stock Overview
| Market Cap in USD | 2,049m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2016-05-06 |
NTLA Stock Ratings
| Growth 5y | 0.04 |
| Fundamental | -80.9 |
| Dividend | - |
| Rel. Performance vs Sector | -6.07 |
| Analysts | 4.43/5 |
| Fair Price Momentum | 17.27 USD |
| Fair Price DCF | - |
NTLA Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
NTLA Growth Ratios
| Growth 12m | -45.01% |
| Growth Correlation 12m | -67% |
| Growth Correlation 3m | -38% |
| CAGR 5y | 4.90% |
| Sharpe Ratio 12m | -0.87 |
| Alpha vs SP500 12m | -82.00 |
| Beta vs SP500 5y weekly | 1.69 |
| ValueRay RSI | 21.25 |
| Volatility GJR Garch 1y | 64.80% |
| Price / SMA 50 | -21.72% |
| Price / SMA 200 | -32.2% |
| Current Volume | 1025.7k |
| Average Volume 20d | 1205.3k |
External Links for NTLA Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 29, 2024, the stock is trading at USD 20.76 with a total of 1,025,682 shares traded.
Over the past week, the price has changed by -4.90%, over one month by -24.54%, over three months by -20.70% and over the past year by -45.01%.
According to ValueRays Forecast Model, NTLA Intellia Therapeutics will be worth about 19.6 in April 2025. The stock is currently trading at 20.76. This means that the stock has a potential downside of -5.39%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 71 | 242 |
| Analysts Target Price | 83.3 | 301 |
| ValueRay Target Price | 19.6 | -5.39 |